What is Ofatumumab treatment?

Ofatumumab (Ofatumumab) is a new type of anti-CD2O monoclonal antibody that can be used alone or in combination. When used alone, it can treat relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The exact mechanism of its action is unknown, but it is speculated to be related to binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes.

Ofatumumab has been used to treat chronic lymphocytic leukemia (CLL) and can be used in combination with chlorambucil to treat previously untreated CLL patients who are considered unsuitable for treatment with fludarabine; it can also be used with fludarabine and Cyclophosphamide is used in combination with fludarabine and alemtuzumab to treat patients with relapsed CLL; it can also be used with fludarabine and alemtuzumab to treat patients with refractory CLL; for patients who have a complete or partial response after at least two courses of treatment for relapsed or progressive CLL, ofatumumab can be used for extended treatment. Ofatumumab causes antibody-dependent cellular lysis and complement-mediated lysis. Data suggest that possible mechanisms of cell lysis include complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

The original drug of ofatumumab is already on the market in China, but it is only used to treat multiple sclerosis. It has also been included in medical insurance and is limited to patients who meet the indications for reimbursement. The price is around tens of thousands of yuan, and it is difficult to purchase it domestically. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.